100 related articles for article (PubMed ID: 22467172)
1. Suppression of Tak1 promotes prostate tumorigenesis.
Wu M; Shi L; Cimic A; Romero L; Sui G; Lees CJ; Cline JM; Seals DF; Sirintrapun JS; McCoy TP; Liu W; Kim JW; Hawkins GA; Peehl DM; Xu J; Cramer SD
Cancer Res; 2012 Jun; 72(11):2833-43. PubMed ID: 22467172
[TBL] [Abstract][Full Text] [Related]
2. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.
Rodrigues LU; Rider L; Nieto C; Romero L; Karimpour-Fard A; Loda M; Lucia MS; Wu M; Shi L; Cimic A; Sirintrapun SJ; Nolley R; Pac C; Chen H; Peehl DM; Xu J; Liu W; Costello JC; Cramer SD
Cancer Res; 2015 Mar; 75(6):1021-34. PubMed ID: 25770290
[TBL] [Abstract][Full Text] [Related]
3. TAK1 regulates hepatic cell survival and carcinogenesis.
Roh YS; Song J; Seki E
J Gastroenterol; 2014 Feb; 49(2):185-94. PubMed ID: 24443058
[TBL] [Abstract][Full Text] [Related]
4. TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.
Inokuchi-Shimizu S; Park EJ; Roh YS; Yang L; Zhang B; Song J; Liang S; Pimienta M; Taniguchi K; Wu X; Asahina K; Lagakos W; Mackey MR; Akira S; Ellisman MH; Sears DD; Olefsky JM; Karin M; Brenner DA; Seki E
J Clin Invest; 2014 Aug; 124(8):3566-78. PubMed ID: 24983318
[TBL] [Abstract][Full Text] [Related]
5. Multifaceted roles of TAK1 signaling in cancer.
Mukhopadhyay H; Lee NY
Oncogene; 2020 Feb; 39(7):1402-1413. PubMed ID: 31695153
[TBL] [Abstract][Full Text] [Related]
6. Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination.
Washino S; Rider LC; Romero L; Jillson LK; Affandi T; Ohm AM; Lam ET; Reyland ME; Costello JC; Cramer SD
Mol Cancer Res; 2019 Oct; 17(10):1985-1998. PubMed ID: 31300540
[TBL] [Abstract][Full Text] [Related]
7. TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma.
Podder B; Guttà C; Rožanc J; Gerlach E; Feoktistova M; Panayotova-Dimitrova D; Alexopoulos LG; Leverkus M; Rehm M
Cell Death Differ; 2019 Dec; 26(12):2520-2534. PubMed ID: 30850732
[TBL] [Abstract][Full Text] [Related]
8. TAK1 regulates endothelial cell necroptosis and tumor metastasis.
Yang L; Joseph S; Sun T; Hoffmann J; Thevissen S; Offermanns S; Strilic B
Cell Death Differ; 2019 Oct; 26(10):1987-1997. PubMed ID: 30683914
[TBL] [Abstract][Full Text] [Related]
9. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.
Cordas Dos Santos DM; Eilers J; Sosa Vizcaino A; Orlova E; Zimmermann M; Stanulla M; Schrappe M; Börner K; Grimm D; Muckenthaler MU; Kulozik AE; Kunz JB
BMC Cancer; 2018 Jun; 18(1):663. PubMed ID: 29914415
[TBL] [Abstract][Full Text] [Related]
10. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction.
Yamaguchi K; Shirakabe K; Shibuya H; Irie K; Oishi I; Ueno N; Taniguchi T; Nishida E; Matsumoto K
Science; 1995 Dec; 270(5244):2008-11. PubMed ID: 8533096
[TBL] [Abstract][Full Text] [Related]
11. ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer.
Orman MV; Sreekanth V; Laajala TD; Cramer SD; Costello JC
Front Pharmacol; 2024; 15():1360352. PubMed ID: 38751776
[TBL] [Abstract][Full Text] [Related]
12. A harmonized resource of integrated prostate cancer clinical, -omic, and signature features.
Laajala TD; Sreekanth V; Soupir AC; Creed JH; Halkola AS; Calboli FCF; Singaravelu K; Orman MV; Colin-Leitzinger C; Gerke T; Fridley BL; Tyekucheva S; Costello JC
Sci Data; 2023 Jul; 10(1):430. PubMed ID: 37407670
[TBL] [Abstract][Full Text] [Related]
13. TAK1 deficiency promotes liver injury and tumorigenesis via ferroptosis and macrophage cGAS-STING signalling.
Su W; Gao W; Zhang R; Wang Q; Li L; Bu Q; Xu Z; Liu Z; Wang M; Zhu Y; Wu G; Zhou H; Wang X; Lu L
JHEP Rep; 2023 May; 5(5):100695. PubMed ID: 36968217
[TBL] [Abstract][Full Text] [Related]
14. Semisynthesis of Hypothemycin Analogues Targeting the C8-C9 Diol.
Al Subeh ZY; Li T; Ustoyev A; Obike JC; West PM; Khin M; Burdette JE; Pearce CJ; Oberlies NH; Croatt MP
J Nat Prod; 2022 Aug; 85(8):2018-2025. PubMed ID: 35834411
[TBL] [Abstract][Full Text] [Related]
15. 6q deletion is frequent but unrelated to patient prognosis in breast cancer.
Lebok P; Bönte H; Kluth M; Möller-Koop C; Witzel I; Wölber L; Paluchowski P; Wilke C; Heilenkötter U; Müller V; Schmalfeldt B; Simon R; Sauter G; Terracciano L; Krech RH; von der Assen A; Burandt E
Breast Cancer; 2022 Mar; 29(2):216-223. PubMed ID: 34625909
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes.
Jillson LK; Yette GA; Laajala TD; Tilley WD; Costello JC; Cramer SD
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34208794
[TBL] [Abstract][Full Text] [Related]
17. The stabilization of yes-associated protein by TGFβ-activated kinase 1 regulates the self-renewal and oncogenesis of gastric cancer stem cells.
Wang G; Sun Q; Zhu H; Bi Y; Zhu H; Xu A
J Cell Mol Med; 2021 Jul; 25(14):6584-6601. PubMed ID: 34075691
[TBL] [Abstract][Full Text] [Related]
18.
Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
[TBL] [Abstract][Full Text] [Related]
19. TAK1 Phosphorylates RASSF9 and Inhibits Esophageal Squamous Tumor Cell Proliferation by Targeting the RAS/MEK/ERK Axis.
Shi H; Ju Q; Mao Y; Wang Y; Ding J; Liu X; Tang X; Sun C
Adv Sci (Weinh); 2021 Mar; 8(5):2001575. PubMed ID: 33717835
[TBL] [Abstract][Full Text] [Related]
20. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
Shorning BY; Dass MS; Smalley MJ; Pearson HB
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
